Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by drjekylon Aug 01, 2017 9:40am
139 Views
Post# 26532703

RE:RE:financials

RE:RE:financialsdigi,
don't you realize that these things take longer than expected.
what i don't understand is that in the year ended february 28, 2017 the company spoke of a corporate highlight being the appointment of MD as president, ceo and a director of the corporation in april.
then its not until the 3 months ended May 31, 2017 that they disclose the engagement of GCP back in march 2017.
jd, before you attack me, know this, I'm not alluding to anything negative, just wondering why it wasn't in there sooner.

drj!
Bullboard Posts